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ABSTRACT
Purpose: Subsets of pituitary tumors exhibit an aggressive clinical courses
and recur despite surgery, radiation, and chemotherapy. Because modulation of
the immune response through inhibition of T-cell checkpoints has led to durable
clinical responses in multiple malignancies, we explored whether pituitary adenomas
express immune-related biomarkers that could suggest suitability for immunotherapy.
Specifically, programmed death ligand 1 (PD-L1) has emerged as a potential
biomarker whose expression may portend more favorable responses to immune
checkpoint blockade therapies. We thus investigated the expression of PD-L1 in
pituitary adenomas.
Methods: PD-L1 RNA and protein expression were evaluated in 48 pituitary
tumors, including functioning and non-functioning adenomas as well as atypical and
recurrent tumors. Tumor infiltrating lymphocyte populations were also assessed by
immunohistochemistry.
Results: Pituitary tumors express variable levels of PD-L1 transcript and protein.
PD-L1 RNA and protein expression were significantly increased in functioning (growth
hormone and prolactin-expressing) pituitary adenomas compared to non-functioning
(null cell and silent gonadotroph) adenomas. Moreover, primary pituitary adenomas
harbored higher levels of PD-L1 mRNA compared to recurrent tumors. Tumor
infiltrating lymphocytes were observed in all pituitary tumors and were positively
correlated with increased PD-L1 expression, particularly in the functional subtypes.
Conclusions: Human pituitary adenomas harbor PD-L1 across subtypes, with
significantly higher expression in functioning adenomas compared to non-functioning
adenomas. This expression is accompanied by the presence of tumor infiltrating
lymphocytes. These findings suggest the existence of an immune response to pituitary
tumors and raise the possibility of considering checkpoint blockade immunotherapy
in cases refractory to conventional management.
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INTRODUCTION

pituitary tumors refractory to conventional treatments
and the recent success of checkpoint blockade
immunotherapies in cancer, we investigated the expression
of PD-L1 in a range of human pituitary tumors. We
determined the level of expression first by RNAscope
analysis, and then confirmed PD-L1 protein expression
by immunohistochemistry. Lastly, we characterized the
immune cell infiltrates in these tumors.

Pituitary tumors are the second most common
intracranial neoplasms, comprising 10-15% of diagnosed
brain tumors [1, 2]. Some pituitary tumors are considered
“functioning” and liberate physiologic hormones
to a pathologic degree to manifest as one of several
classic endocrinologic syndromes. Specifically, tumors
producing growth hormone (GH) or adrenocorticotropic
hormone (ACTH) are associated with significant
systemic medical morbidity. In contrast, other pituitary
tumors are hormonally silent (non-functioning) but may
compress adjacent neurovascular structures during growth,
conferring degrees of visual loss, pituitary dysfunction,
and cranial neuropathies. Although often cured by
surgery alone or controlled medically, as in the case of
most prolactin-secreting tumors, recurrence rates are not
insignificant. In a large cohort of patients followed for 10
years after transsphenoidal surgery, rates of recurrence
across tumor subtypes varied between 6-25% [3]. In
the recurrent setting, adjuvant medical treatments in
functioning and non-functioning tumors are only variably
effective in durable tumor control, and radiotherapy
may be limited by proximity to the optic nerves. Other
subclasses of pituitary tumors that may be difficult to
manage include atypical adenomas and those that invade
the cavernous sinus and surround one or both cavernous
carotid arteries. Overall, there are a limited number of
adjuvant treatment options for clinically challenging
pituitary tumors.
The use of immune-based therapies has led to
durable clinical responses in patients with a range of
systemic cancers [4-7]. In particular, treatments that block
T cell “checkpoints”—such as the negative regulator
proteins cytotoxic T-lymphocyte-associated protein
4 (CTLA-4) and programmed cell death 1 (PD-1)/
programmed death ligand-1 (PD-L1)—unleash tumorspecific immune responses and are now FDA-approved
to treat melanoma, lung cancer, and renal cell carcinoma.
PD-1 is inducible on tumor infiltrating lymphocytes [8-11],
while one of its ligands, PD-L1, may be overexpressed by
tumor cells or antigen-presenting cells. The binding of PDL1 to PD1 represents an “immune checkpoint” in that it
impairs the function of activated lymphocytes in peripheral
tissues [12-16], providing a potential mechanism by
which tumors may evade the immune response [14, 17,
18]. Importantly, in several cancers, PD-L1 expression
is positively correlated with improved responses to antiPD-1/PD-L1 blockade [5, 18], though immunotherapy has
also been shown to benefit of a subset of patients whose
tumors do not express PD-L1 [19, 20]. Recently, PD-L1
was found to be highly expressed in both glioblastoma
[21, 22] as well as high-grade meningioma [23], raising
the possibility of checkpoint inhibition in central nervous
system tumors, for which clinical trials are ongoing.
Thus, due to the dearth of adjuvant therapies for
www.impactjournals.com/oncotarget

RESULTS
Pituitary adenomas express variable levels of PDL1
We first assessed PD-L1 expression profiles in
pituitary tumors by investigating mRNA and protein levels
across pituitary adenomas. We used RNAscope in situ
hybridization to detect PD-L1 mRNA and IHC to assess
PD-L1 protein expression. Across all pituitary adenomas,
variable expression of PD-L1 was observed (Figure 1),
with a 10-fold difference in protein levels and a 5-fold
difference across mRNA signals.

PD-L1 mRNA and protein levels are increased
in functioning adenomas compared to nonfunctioning adenomas
We next explored the relationship between PDL1 expression and subclasses of pituitary adenomas.
Comparison of functioning (GH and PRL expressing, n =
28) and non-functioning (null cell and silent gonadotroph,
n = 20) adenomas revealed significantly higher mRNA
levels in the functioning tumors (p = 0.023, Figure 2AB). Consistent with PD-L1 transcript levels, functioning
adenomas harbored statistically higher PD-L1 protein
expression compared to non-functioning adenomas (p
= 0.039, Figure 2C-D). However, little correlation was
observed between PD-L1 mRNA and protein levels
at an individual sample level (Supplementary Figure
1). Somatotroph adenomas and mammosomatotroph
adenomas did not vary significantly in their PD-L1
expression.

PD-L1 is expressed in recurrent and atypical
adenomas
We next investigated PD-L1 levels in recurrent and
atypical pituitary adenomas, classes of tumors that can be
challenging to manage with existing treatment strategies.
PD-L1 transcript, but not protein levels, was significantly
elevated in primary (n = 34) compared to recurrent (n
= 14) pituitary adenomas (p = 0.0048 for transcript, p
= 0.316 for protein, Figure 3). Atypical tumors were
76566
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classified by WHO criteria, as adenomas with excessive
p53 immunoreactivity or increased mitotic activity [1].
While PD-L1 mRNA and protein are expressed, they did
not vary significantly between adenomas with typical
(n = 37) or atypical (n = 11) status (p = 0.54 and 0.21,
respectively, Figure 4).
The MIB-1 proliferative index has been shown to
independently predict tumor recurrence or invasiveness
and is elevated in atypical adenomas [26, 27]. We
further examined the expression of PD-L1 in adenomas

with MIB-1 ≤ 3% (n = 20) or MIB-1 > 3% (n = 28). No
significant correlation was observed between PD-L1
mRNA or protein expression and MIB-1 index (Figure 5).

Characterization of the immune infiltrate of
pituitary tumors in tissue specimens
Having characterized PD-L1 expression in our
cohort of pituitary tumors, we investigated the presence
of lymphocytic infiltrate in these specimens. We stained

Figure 1: PD-L1 expression across pituitary adenomas. Quantification of PD-L1 mRNA (left y-axis) and protein (right y-axis)

levels across all pituitary tumors in the cohort reveals diversity in expression. Samples within each scatter plot are divided into quartiles,
centered around the median.
www.impactjournals.com/oncotarget
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Figure 2: PD-L1 mRNA and protein expression in functioning and non-functioning pituitary tumors. A. Quantification
of PD-L1 RNAscope staining in functioning (n = 28) and non-functioning (n = 20) pituitary adenomas. B. In situ hybridization of PD-L1
mRNA using a PD-L1-specific RNAscope probe in a functioning (GH) and a non-functioning (null cell) pituitary tumor. C. Quantification
of PD-L1 IHC staining in functioning and non-functioning pituitary adenomas. D. IHC staining of PD-L1 protein in a functioning (GH) and
a non-functioning (null cell) pituitary adenoma. *p < 0.05, scale bar 50µm.

Figure 3: PD-L1 mRNA and protein expression in primary and recurrent pituitary tumors. A. Quantification of PD-L1

RNAscope staining in primary (n = 34) and recurrent (n = 14) pituitary adenomas. B. RNAscope staining of PD-L1 mRNA in a primary
and a recurrent pituitary tumor. C. Quantification of PD-L1 IHC staining in primary and recurrent pituitary adenomas. D. IHC staining of
PD-L1 protein in a primary and a recurrent pituitary adenoma. *p < 0.05, scale bar 50 µm.
www.impactjournals.com/oncotarget
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DISCUSSION

TMAs with antibodies targeting a pan-lymphocyte marker
(CD45), T cell markers (CD3, CD4, CD8) and the immune
regulatory receptor PD-1. An analysis of all tumors taken
together shows variable CD3, CD4, CD8, CD45, and PD-1
expression (Figure 6).
When analyzed by subclass of tumor (Figure 7),
both CD3+ and CD4+ populations were significantly
increased in functioning adenomas compared to nonfunctioning adenomas (p = 0.019 and p = 0.0001,
respectively). All lymphocytic infiltrate markers appeared
higher in adenomas with an elevated proliferative index,
with a significantly increased expression in CD45+ cell
infiltrates in adenomas with high (MIB-1 > 3%) compared
to low (MIB-1 ≤ 3%) proliferative indices (p = 0.0093).
Furthermore, CD3+, CD4+, and CD45+ cells trended to
a higher expression in atypical adenomas compared to
typical adenomas. PD-1 was significantly increased in
non-functioning adenomas (p = 0.0018) and those with
elevated proliferative indices (p = 0.003), while being
comparable in primary and recurrent tumors.

Substantial work over the last fifteen years has
begun to clarify the complex relationship between the
immune system and cancer. Specifically, the “cancer
immunoediting hypothesis” articulates that tumors
dynamically evolve to evade immune responses in order
to grow progressively [28]. This shared cancer phenotype
of immunoevasion is recognized as a “hallmark of cancer”
[29]. Capitalization on the molecular basis of immune
regulation has led to the application of checkpoint
blockade immunotherapy in several tumor types, with
durable clinical responses in some patients with advanced
metastatic cancer.
We investigated several immunological parameters
in pituitary tumors with the goal of exploring new
therapeutic avenues for treatment-refractory tumors.
In particular, the location of the pituitary gland outside
the blood brain barrier may render systemic therapies
more effective. Using in situ RNA hybridization and

Figure 4: PD-L1 mRNA and protein expression in typical and atypical pituitary tumors. A. Quantification of PD-L1

RNAscope staining in typical (n = 37) and atypical (n = 11) pituitary adenomas. B. RNAscope staining of PD-L1 mRNA in a typical and
an atypical pituitary tumor. C. Quantification of PD-L1 IHC staining in typical and atypical pituitary adenomas. D. IHC staining of PD-L1
protein in a typical and an atypical pituitary tumor. Scale bar 50µm.
www.impactjournals.com/oncotarget
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The interaction between PD-L1 and the PD-1
receptor on T cells leads to an inhibitory signal that
constrains the function of activated lymphocytes
[33]. Thus, PD-L1 overexpression is postulated to be
a strategy employed by tumors to evade anti-tumor
immune responses. Several mechanisms underlying PDL1 upregulation have been described that can broadly
be considered either “intrinsic” or “extrinsic” in nature.
Specifically, increased PD-L1 expression appears to be
driven by a number of cell-intrinsic programs—in the
setting of PTEN loss in malignant brain tumors [21],
activating EGFR mutations in non-small cell lung cancer
[34], and increased STAT3 and AP-1 transcriptional
activation in BRAF-mutant melanomas resistant to
BRAF inhibition [35]. Alternatively, cytokines produced
in the tumor microenvironment may also drive PDL1 expression in an “extrinsic” manner. For instance,
interferon-gamma secretion by lymphocytes leads to
target cell PD-L1 upregulation. This finding stimulated the

immunohistochemistry, we assessed the expression of the
immunoregulatory checkpoint molecule PD-L1 as well
as the infiltrating lymphocyte population within a broad
range of pituitary tumors. Together, our findings are the
first to demonstrate expression of both PD-L1 mRNA
and protein in pituitary tumors irrespective of tumor
hormone secretion, proliferative index, aggressiveness
level, or recurrence status. Previous studies have reported
the presence of T-cell enriched populations of tumor
infiltrating lymphocytes in pituitary adenomas [30,
31]. Functional subtypes (e.g. GH adenomas) appear to
demonstrate greater degrees of lymphocyte infiltration
than non-functional tumors [32]. In our study, functional
pituitary tumors exhibited more frequent lymphocytic
infiltration than non-functional tumors, consistent with
previous observations [31]. Ongoing work is directed at
expanding our analysis in order to increase our statistical
power to clarify the tumor-to-tumor differences in immune
cell subsets and cell surface activation markers.

Figure 5: Correlation between MIB-1 proliferative index and PD-L1 expression in pituitary adenomas. A. Quantification

of PD-L1 RNAscope staining in pituitary adenomas with different proliferation indices. B. RNAscope staining of PD-L1 mRNA in pituitary
adenomas with different proliferation indices. C. Quantification of PD-L1 IHC staining in pituitary adenomas with different proliferation
indices. D. IHC staining of PD-L1 protein in pituitary adenomas with different proliferation indices. Scale bar 50µm.
www.impactjournals.com/oncotarget
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concept of “adaptive immune resistance” whereby tumor
cells responding to anti-tumor lymphocytes may increase
the expression of inhibitory molecules such as PD-L1 [16].
Concomitant presence of lymphocyte populations and PDL1 expressing cells in pituitary adenomas, as shown in
this study, suggests that pituitary tumors might invoke
such an adaptive immune resistance mechanism, although
the possibility of concomitant intrinsic programs remain.
Further work will be needed to determine whether these,
or other novel, regulatory pathways converge on PD-L1
overexpression in pituitary tumors.
The selective increase in PD-L1 expression observed

in functional pituitary tumors raises a number of future
areas of investigation. Our group has characterized the
genomic landscape of a broad range of pituitary adenomas
including functional and non-functional tumors, and there
do not appear to be recurrent alterations in some of the
genes, such as PTEN and EGFR, that have been implicated
in PD-L1 upregulation in other tumor types. However, we
observed significant differences in broad copy number
alterations in the functional subset compared to other
pituitary tumors. Ongoing work is directed at exploring
whether (a) other shared signaling pathway components
downstream of PTEN and EGFR alterations may be more

Figure 6: Immune infiltrate markers and PD-1 expression across pituitary adenomas. Pituitary tumors express variable
levels of A. lymphocytic markers, including the T-lymphocyte markers CD3, CD4, and CD8, as well as the pan-lymphocyte marker CD45,
and B. PD-1. Protein expression is normalized to intensity/cell surface area. Samples within each scatter plot are divided into quartiles,
centered around the median.
www.impactjournals.com/oncotarget
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activated in functional tumors; (b) there are recurrent
copy number alterations in pathway components that
may be relevant to PD-L1 expression or regulation; and
(c) a globally altered copy number state itself may be an
activator of PD-L1 upregulation.
The clinical success of PD-1/PD-L1 blockade has
generated enthusiasm in exploring the spectrum of tumor

types that may respond to checkpoint inhibition. However,
although durable responses to PD-1/PD-L1 therapies have
been observed in a range of cancers including melanoma,
non-small cell lung cancer, and renal cell carcinoma [36],
reliable biomarkers to predict who will respond to immune
blockade are still lacking. Presently, substantial work has
centered on the use of PD-L1 as a predictive biomarker

Figure 7: Characterization of the immune infiltrate of pituitary tumors in tissue specimens. A. Pan-lymphocyte marker

CD45 expression in pituitary tumors classified according to tumor function, recurrence status, aggressiveness level, or proliferation status.
B. CD3+ T lymphocyte, C. CD4+ T lymphocyte, D. CD8+ T lymphocyte and E. PD-1 expression in pituitary tumors. *p < 0.05.
www.impactjournals.com/oncotarget
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[37], which motivated our analysis of its expression in
pituitary tumors. Initial studies showed patients whose
tumors exhibited PD-L1 expression demonstrated
improved clinical responses compared to patients with PDL1 negative tumors when treated with the ant-PD-1 drug,
nivolumab [5] or pembrolizumab [38]. Moreover, a recent
study in which patients with urothelial cancer were treated
with the anti-PD-L1 agent, atezolizumab, showed that PDL1 expression on tumor immune infiltrate was associated
with improved clinical responses [6]. Intriguingly, both
high-grade meningioma and high-grade glioma show
increased rates of PD-L1 expression, suggesting that
PD-L1 may correlate both with tumor aggressiveness
and potential response to therapy [39, 40]. However,
additional studies have shown that patients with PD-L1
negative tumors may also exhibit clinical responses to
anti-PD-1 therapies [41, 42]. Recent work has highlighted
the complex regulation of PD-L1 levels, with posttranslational modifications playing a substantial role in
modulating protein levels [43]. Furthermore, there appears
to be large assay-to-assay variability in the assessment
of PD-L1 levels, complicating efforts to use expression
as a pre-requisite for trial enrollment [20]. Our current
understanding of the relationship between observed PDL1 levels and response to immunotherapy is incomplete,
and this remains an active area of investigation across a
variety of disciplines. Of note, immunotherapy has been
associated with treatment-related hypophysitis, which may
be especially relevant in patients with pituitary tumors
who are already vulnerable to tumor-related pituitary
dysfunction [44].
Other groups have attempted to stratify tumors by
the presence of tumor infiltrating lymphocytes and PDL1 and have used these parameters to create 4 tumor
types—i.e, TIL+PD-L1+, TIL-PD-L1+, TIL+PD-L1-,
and TIL-PD-L1- [45, 46]. There is growing support that
“TIL+PD-L1+” tumors may have the best chance to respond
to checkpoint immunotherapy. Thus, in our dataset, it is
possible that functional and primary adenomas—in which
there is high PD-L1 as well as increased T cells—may be
particularly responsive to anti- PD-L1 therapy. In contrast,
slowly proliferative pituitary tumors—in which there are
decreased T cells that do not express PD-1, lower PD-L1
expression, and may be anergic or hypoactive—may be
less responsive. In other CNS tumors, the presence of
tumor infiltrating lymphocytes (TILs) has been correlated
with improved survival in several malignancies, including
gliomas, and is being examined as a potential prognostic
biomarker. We anticipate that intracranial tumors may
actually harbor distinct immunologic microenvironments
depending on location—e.g., extradural or intradural,
proximity to commissural organs, and such—and therefore
additional work is needed to understand how distinct
intracranial compartments differ. Ultimately, although
tumor cell PD-L1 expression may predict clinical response
to anti-PD-1/PD-L1 therapy, it is clear that additional work
www.impactjournals.com/oncotarget

is needed to clarify the full scope of its predictive power as
well as the contributions of other in situ parameters.

MATERIALS AND METHODS
Sample selection and preparation
Formalin-fixed, paraffin-embedded human pituitary
tumor specimens were collected from the Department
of Pathology, Brigham and Women’s Hospital, with
corresponding clinical records and pathology reports.
Hematoxylin and eosin stained sections corresponding
to each tumor were reviewed by two neuropathologists
(MA, SS) for selection of specimens with greater than
70% estimated tumor purity. 48 tumors (with duplicate
cores for most specimens, spanning 94 samples total)
were compiled in tissue microarray (TMA) format for
subsequent analysis. The study was approved by the
Institutional Review Boards of Brigham and Women’s
Hospital and Dana Farber Cancer Institute, Harvard
Medical School.
Growth hormone (GH) and prolactin (PRL)
secreting tumors were classified as functioning. Only two
ACTH-expressing adenomas were in the cohort and were
excluded from analysis. Null cell adenomas and silent
gonadotroph adenomas were classified as nonfunctioning.

RNAscope in situ hybridization
PD-L1 transcript levels were detected using
RNAscope 2.0 HD brown detection kit (Advanced
Cell Diagnostics, Hayward, CA). A custom-designed
RNAscope probe (courtesy of Santagata laboratory) was
used to stain the pituitary adenoma TMA. As described
previously [23], 5 μm paraffin-embedded TMA sections
were baked and deparaffinized, and then boiled with
pretreatment reagent for 15 minutes. Protease digestion
was performed at 40ºC for 30 minutes, followed by
hybridization for 2 hours at 40ºC with Probe-Hs-PDL1-v2
(Advanced Cell Diagnostics, Hayward, CA). The signal
was visualized with 3,3’-Diaminobenzidine (DAB)
and cell nuclei were counterstained with hematoxylin.
Probe-DapB (Advanced Cell Diagnostics, Hayward,
CA) and Probe-Hs-PPIB (Advanced Cell Diagnostics,
Hayward, CA) were used as negative and positive control,
respectively. All slides were digitally scanned using Carl
Zeiss Microimaging (Jena, Germany).

RNAscope analysis
RNAscope staining was analyzed using CellProfiler
image analysis software (http://www.cellprofiler.
org/) [24]. The pipeline was previously optimized for
76573
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meningioma TMAs (http://cellprofiler.org/examples/
published_pipelines.html) [23]. Briefly, the image was
split into hematoxylin and DAB immunopositive layers
with the “Unmixcolors” module. Then, the background
was removed and the DAB staining spots were highlighted
with the “EnhanceOrSuppressFeatures” module. Finally,
the relation of spots with their host cells was identified
with the “RelateObjects” module. Optimization for
the scoring of pituitary tumors was accomplished by
adjustment of the threshold for detecting nuclei and in
situ hybridization signals (dots). The average number of
dots per cell in each pituitary case was compared across
groups. False positive recognition of stromal cells such
as blood cells in regions of hemorrhage as well as dark
staining of some nuclei by the counterstain were excluded
by visual review. Cases with staining artifacts or poor
tissue integrity following hybridization processing were
excluded.

nih.gov/ij/). Single DAB stained images were obtained
using color deconvolution. After adjustment of the color
threshold, the intensity of the DAB positive staining was
measured. A mean value (intensity/area) was used for
statistical analysis. PD-L1 IHC staining intensity was
also measured using color deconvolution and quantified
by Image J. PD-1 and CDs IHC staining were quantified
by blinded counting. Cases with staining artifacts or
poor tissue integrity following immunohistochemical
processing were excluded.

Statistical analysis
Results are expressed as median ± interquartile
range, within minimum to maximal values. Statistical
analysis was performed using GraphPad Prism (GraphPad,
La Jolla, CA), and comparisons were made using unpaired
Mann-Whitney test. A p value < 0.05 was considered
significant.

Immunohistochemistry

Abbreviations

Pituitary TMA slides were baked at 60°C for one
hour to melt excess paraffin. Immunohistochemistry
(IHC) staining for CD3 (1:250, Dako, Carpinteria, CA),
CD4 (1:80, Dako, Carpinteria, CA), CD8 (1:100, Dako,
Carpinteria, CA), CD45 (1:50, Dako, Carpinteria, CA),
PD-L1 (courtesy of Gordon Freeman and validated
previously [23], 1:125, diluted in Ventana diluent) and
PD-1 (courtesy of Gordon Freeman, 1:1000, diluted in
Bond diluent) was performed on a Bond III automated
IHC stainer using the Bond Refine Detection Kit (Leica
Biosystems, Buffalo Grove, IL). Antigen retrieval was
performed using Bond Epitope Retrieval 2 system for
30 minutes. Tissue stained for PD-L1 used an optimized
protocol for PD-L1 that consisted of two hour primary
antibody incubation, while tissue stained for PD-1 and
CDs utilized an optimized protocol that consisted of a 30
min primary antibody incubation. Slides were dehydrated
in 85-100% ethanol, mounted using xylene, and coverslipped. All slides were digitally scanned using Carl Zeiss
Microimaging (Jena, Germany).
Murine B cells transfected with human PD-L1 gene
served as a positive control for PD-L1 IHC antibody
testing (Supplementary Figure 2A-B). Human tonsil
tissue are known to harbor robust PD-1 protein expression
within germinal centers, but not outside of them, and
served as the control tissue for PD-1 IHC antibody testing
(Supplementary Figure 2C).

ACTH, adrenocorticotropic hormone; CTLA4, cytotoxic T-lymphocyte-associated protein 4; DAB,
3, 3’-Diaminobenzidine; FSH, follicle-stimulating
hormone; GH, growth hormone; IFNγ, interferon-γ;
IHC, immunohistochemistry; LH, luteinizing hormone;
PD-1, programmed cell death-1; PD-L1, programmed
death-ligand 1; PRL, prolactin; TIL, tumor infiltrating
lymphocyte; TMA, tissue microarray; TSH, thyroidstimulating hormone.
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